The tripeptide feG ameliorates systemic inflammatory responses to rat intestinal anaphylaxis
Fusun Turesin, Aida Sadr, Joseph S Davison and Ronald Mathison*

Address: Faculty of Medicine, Department of Physiology and Biophysics, University of Calgary, Calgary, Alberta T2N 4N1, USA
E-mail: Fusun Turesin - fturesin@ucalgary.ca; Aida Sadr - asadr@ualberta.ca; Joseph S Davison - jdavison@ucalgary.ca; Ronald Mathison* - rmathiso@ucalgary.ca
*Corresponding author

Abstract

Background: Food allergies are generally associated with gastrointestinal upset, but in many patients systemic reactions occur. However, the systemic effects of food allergies are poorly understood in experimental animals, which also offer the opportunity to explore the actions of anti-allergic drugs. The tripeptide D-phenylalanine-D-glutamate-Glycine (feG), which potentially alleviates the symptoms of systemic anaphylactic reactions, was tested to determine if it also reduced systemic inflammatory responses provoked by a gastric allergic reaction.

Results: Optimal inhibition of intestinal anaphylaxis was obtained when 100 µg/kg of feG was given 20 min before the rats were challenged with antigen. The increase in total circulating neutrophils and accumulation of neutrophils in the heart, developing 3 h and 24 h, respectively, after antigen challenge were reduced by both feG and dexamethasone. Both anti-inflammatory agents reduced the increase in vascular permeability induced by antigen in the intestine and the peripheral skin (pinna), albeit with different time courses. Dexamethasone prevented increases in vascular permeability when given 12 h before antigen challenge, whereas feG was effective when given 20 min before ingestion of antigen. The tripeptide prevented the anaphylaxis induced up regulation of specific antibody binding of a cell adhesion molecule related to neutrophil activation, namely CD49d (α4 integrin).

Conclusions: Aside from showing that intestinal anaphylaxis produces significant systemic inflammatory responses in non-intestinal tissues, our results indicate that the tripeptide feG is a potent inhibitor of extra-gastrointestinal allergic reactions preventing both acute (30 min) and chronic (3 h or greater) inflammatory responses.

Background

Type 1 or IgE-mediated allergic reactions play an important role in food sensitivity reactions [1]. These reactions affect gut motility [2–4], absorption and secretion by the intestinal epithelium [5–7], and enteric as well as central nervous system function [8–11]. Systemic anaphylactic reactions, initiated outside the gastrointestinal tract, have pronounced impact on its integrity and function [12,13], but few studies have determined the impact of intestinal anaphylaxis on other tissues and organs.
Figure 1
**White blood cells after intestinal anaphylaxis.** Time course of total cells (A) and neutrophils (B) in heart blood of ovalbumin sensitized rats receiving either saline (Control), antigen p.o. (Ag), feG (100 µg/kg, p.o.) and antigen (feG + Ag), or dexamethasone (4 mg/kg; i.p.) & antigen (Dex + Ag). Number of animals = 4 to 6. Significance (P < 0.05): * greater than Control; τ less than Ag at time indicated; # less than Control; ϕ greater than Ag and Ag + feG at times indicated.
In experimental animals minor and infrequent respiratory and cardiovascular effects after oral challenge with antigen in sensitized Brown Norway rats were reported [14]. However, systemic anaphylactic reactions involving the cutaneous, respiratory and cardiovascular systems following ingestion of food are fairly common in humans as they occur with 10–30% of sensitized individuals [15–18]. In our own studies, where the presence of diarrhea was used as a clinical sign of intestinal anaphylaxis in orally challenged ovalbumin sensitized Hooded-Lister rats [19–21], frequent piloerection was observed. This observation led us to suspect that systemic effects of intestinal anaphylaxis may be subtler than expected, and we decided to examine the hematological and vascular permeability changes associated with intestinal anaphylaxis. In these earlier studies we described protective effects of a heptapeptide, submandibular gland peptide-T (SGP-T) and its associated fragments, the tripeptide FEG and its D-isomeric form feG, on gastrointestinal function with orally administered antigen [19,20,22].

The present investigations examine systemic effects of oral antigen challenge of ovalbumin sensitized Hooded-Lister rats. The circulating neutrophilia, increases in vascular permeability, neutrophil accumulation in the heart and activation of cell adhesion molecules caused by oral ingestion of antigen were significantly reduced by the tripeptide – feG.

**Results**

**Blood cell counts**

Changes in total white blood cell counts were only seen at 3 h after antigen challenge (Figure 1A). A significant increase was observed in rats receiving only antigen (7.8 ± 0.5 × 10^6 cells/mL), relative to sensitized control rats (5.6 ± 0.4 × 10^6 cells/mL). This increase was prevented by the treatment with feG (6.0 ± 0.55 × 10^6 cells/mL). The rats treated with dexamethasone experienced a sharp drop in their total white blood cell counts (3.2 ± 0.4 × 10^6 cells/mL) at 3 h after antigen challenge. At this time a significant increase in circulating neutrophils was seen, a sharp drop in their total white blood cell counts (3.2 ± 0.4 × 10^6 cells/mL) at 3 h after antigen challenge. This increase was prevented by treatment with feG and dexamethasone, although at 24 h neutrophil number increased more than five fold from 6.0 ± 0.5 (×10^5) cells/mL to 33.5 ± 5.2 (×10^5) cells/mL in the dexamethasone, but not feG, treated rats. No changes were seen in the number of circulating lymphocytes at any of the time points sampled (not shown).

**Hematocrit**

Intragastric challenge with antigen did not modify hematocrit, relative to unchallenged sensitized rats (40.4 ± 0.8%), at any of the time points tested. However, rats treated with feG experienced a small decrease in hematocrit at 0.5 h after antigen challenge (39.1 ± 0.5%). In contrast, dexamethasone treated rats had significantly higher hematocrit values, than the other 3 groups of animals, at 0.5 h (45.6 ± 0.4%) and 24 h (45.5 ± 1.8%), but not at 3 h (40.2 ± 0.6%) post-challenge.

**Bone marrow counts**

The effect of intestinal anaphylaxis and the treatment with feG on bone marrow counts was examined at 3 h after antigen challenge. In control-sensitized rats the bone marrow was 13.6 ± 1.2 (×10^6 cells), and this was not significantly altered by either antigen alone 11.0 ± 1.4 (×10^6 cells) or in feG-treated challenged rats 11.1 ± 1.0 (×10^6 cells).

**Vascular permeability changes**

The acute (30 min) changes in vascular permeability induced by antigen in the pinna, jejunum and duodenum was prevented by feG, but not by dexamethasone, when these compounds were given 20 min before antigen challenge (Table 1). On the other hand dexamethasone prevented the changes in vascular permeability provoked by antigen when given 12 h before initiation of the allergic reaction, whereas this prior treatment with feG was ineffective. Antigen challenge alone or in drug treated rats did not affect vascular permeability in the heart or the trachea (not shown).

**Leukocyte infiltration into the heart**

Leukocyte infiltration into the heart, measured with the MPO assay, increased ~75% in OA challenged animals (0.69 ± 0.09 units/mg tissue) relative to controls (0.40 ± 0.05 units/mg tissue) at 24 h after antigen challenge (Figure 2). Treatment with feG or dexamethasone at the time of antigen challenge prevented this accumulation of neutrophils in the myocardium. Interestingly, at 3 h after antigen challenge the MPO content of the heart decreased, relative to control animals, in both feG and dexamethasone treated rats. Only at 0.5 h were significant changes in tissue MPO content of the lung seen, with feG treated rats exhibiting a decrease from 1.01 ± 0.08 units/mg tissue to 0.79 ± 0.08 units/mg tissue. On the other hand, at 24 h after antigen challenge dexamethasone treatment resulted in a significant increase in MPO activity to 1.55 ± 0.03 units/mg of lung tissue.

**Cell adhesion marker expression**

To investigate a relationship between the effects of feG on CD11b and CD49d expression, these antigens were measured on the surface of peritoneal neutrophils isolated from sensitized rats 24 h after exposure to antigen and treatment with feG or the saline vehicle. The inhibitory effect of feG, seen on basal expression of CD11b was not observed in rats that had received an antigen challenge 24 h previously (Figure 3). CD49d was not modified by sen-
sitization or antigen challenge, but feG treatment significantly reduced the expression of this adhesion molecule in OA-exposed animals to values that were 50% of those measured in rats receiving antigen only.

**Interstitial cells in intestinal smooth muscle**
Twenty-four hours after the administration of oral antigen a decreased number of cells expressed the CD18 marker in the smooth muscle of the jejunum (Table 2). This reduction was partially reversed in animals receiving feG. Two morphological distinct leukocytes that stained for ED9 (LPS receptor) could be identified. One type was round and displayed the typical nucleus structure of neutrophils, and the other type had the stellate shape of interstitial macrophages. The number of macrophage-like leukocytes binding ED9 antibody was not affected by antigen challenge, whereas there was a 70% decrease in the number of ED9+ neutrophils. This decrease was significantly reduced by feG.

**Discussion**
Aside from the general malaise and gastrointestinal discomfort that food allergic individuals experience, pronounced respiratory and cardiovascular effects resulting in serious discomfort and requiring medical intervention are uncommon, but when they occur a medical emergency may ensue [15,17]. As with humans, severe systemic reactions in animal models of food allergy are uncommon, although in a rat model, the orally sensitized and -challenged Brown Norway rats, some animals exhibited minor respiratory and cardiovascular changes [14]. Oral antigen challenge of the adjuvant-primed intraperitoneally sensitized Hooded-Lister rats also produces both intestinal and systemic reactions [3,4]. These two animal models of sensitization can produce an IgE-dependent intestinal allergic reaction yielding an anaphylaxis-dependent increase in intestinal permeability [5,14]. A distinguishing feature of the Hooded-Lister rat model is diarrhea; a clinical response that has not been reported in other animal models of intestinal allergy.

Our results indicate that gastrointestinal anaphylaxis results in significant systemic effects. Changes in vascular permeability occurred with 0.5 h, peripheral blood neutrophilia appeared at 3 h, and significant accumulation of neutrophils in the heart was seen at 24 h after antigen challenge. Several factors could contribute to the extra-intestinal manifestations of intestinal allergic reactions, including the vascular leak of antigen [23] activation of peripheral mast cells [14], appearance of intestinal mast cell mediators in the blood [21], and/or a neurogenic reflex [9]. The absence of an increased vascular leak in the trachea following gastric administration of antigen (Table 2), contrasts with the effects of intravenous [24] or airways [25,26] application of the sensitizing allergen. These differences may relate to the species used, as pulmonary allergic reactions have never been reported for Hooded-Lister rats. As seen in other species of rats, even with intravenous challenge with antigen [24,13], we found no vascular leak into the heart with an anaphylactic reaction.

Although anaphylactic reactions induced by intraperitoneal [27] or intravenous [28] administration of antigen are generally accompanied by marked and rapid hemoconcentration, the intestinal hypersensitivity reaction did not produce significant modification of hematocrit, even with the observed increases in vascular permeability. This absence of hemoconcentration indicates a much less severe systemic anaphylaxis following oral challenge with antigen than occurs when the antigen is applied directly into the circulation. Nonetheless, the delayed (3 h) blood neutrophilia (Figure 1) seen after oral antigen also indicates that intestinal anaphylaxis has hematological consequences. Circulating neutrophilia may be a hallmark of anaphylactic reactions as they are also observed in mon-
Figure 2
Neutrophil accumulation in heart and lungs. Time course of myeloperoxidase content of the heart (A) and lungs (B) of ovalbumin sensitized rats receiving either saline (Control), antigen p.o. (Ag), feG (100 µg/kg, p.o.) and antigen (feG + Ag), or dexamethasone (4 mg/kg; i.p.) & antigen (Dex + Ag). Number of animals = 4 to 6. Significance (P < 0.05): # less than Control; τ less than Ag at time indicated; ϕ greater than Ag and Ag + feG at times indicated.
keys [31], and in rats using different methods of sensitization and routes of antigen administration [29,30]. A notable exception is the neutropenia seen in guinea pigs [32].

Anaphylaxis has important effects on neutrophils as exemplified by their early (3 h) loss, but late (24 h) increase in the heart (Figure 2), and decrease in intestinal smooth muscle (Table 1). This early loss of neutrophils from the heart could represent an allergy-mediated degranulation of the tissue resident neutrophils, and subsequent degradation of the enzyme, whereas the late-phase neutrophilia (24 h) reflects a net migration of cells into the myocardium consequent to action of release of mediators of anaphylaxis. The reduced number of ED9+ neutrophils in intestinal muscle was also seen with rats receiving intraperitoneal lipopolysaccharide [33], and may represent a loss of the ED9 cell marker with a phenotypic change to the interstitial neutrophils [34] following the inflammatory insult. Although direct injury to the heart, such as occurs with ischemia-reperfusion injury [35] and other forms of cardiomyopathy [36], are accompanied by pronounced neutrophil influx into the damaged tissue, the current report is the first description of anaphylaxis induced accumulation of neutrophils in the heart. Left ventricular contraction is compromised with systemic anaphylaxis [37], and our results suggest that mild anaphylactic reactions, as may occur with a gastrointestinal reaction, could have deleterious, and long term, effects on the heart. The accumulation of neutrophils in the myocardium may in part be reduced by the peptide feG consequent to decreased expression of α4 integrin (CD49d) from neutrophils (Figure 3), since the adherence of neutrophils to cardiac tissue is mediated primarily by α4β1 integrin [38,39].

This action on CD49d indicates that a reduction in cell adhesion by interfering with integrins may be an important component of feG’s anti-inflammatory effects directly upon inflammatory leukocytes. The prevention, by feG, of the decrease in resident intestinal neutrophils, blood neutrophilia and vascular leak concord with this proposed mechanism since these three processes are integrin dependent [40–42]. In several respects feG is distinguished from anti-inflammatory steroids, especially with regards to a shorter onset and duration of action, and an absence of some of the pro-inflammatory effects, such as circulating and pulmonary neutrophilia. These differences in anti-inflammatory actions between feG and dexamethasone probably relate to the time delay of 4 h to 12 h associated with the steroids actions as a transcription inhibitor.

Figure 3  
**Cell adhesion molecules on peritoneal neutrophils.** Changes in mean flourescence intensity (MFI) for CD11b and CD49d on peritoneal neutrophils in sensitized rats that were either untreated (Control), received feG alone (feG), only antigen (Ag) or both antigen and feG (Ag + feG). Significance: (P < 0.05): # less than Control; * greater than Control; τ less than Ag at time indicated.
[43], which, however, eventually results in reduced integrin expression on leukocytes [44].

Food allergy in humans frequently results in digestive, cutaneous, respiratory and cardiovascular reactions [15–18], however detection of allergen-induced cardiovascular inflammation in humans would be difficult, and to our knowledge food allergen induced cardiac inflammation in humans has never been reported. However, co-inflammatory insults, such as food allergy, that cause activation of cardiac resident mast cells or enhance inflammatory cell infiltration should be avoided in patients with an ongoing inflammation of the heart, i.e. myocarditis, dilated cardiomyopathy, ischemic cardiac injury and unstable angina [35,36,45,46]. The utility of feG in treating allergen-induced inflammations in humans has not been tested, and if such a use was contemplated the peptide would probably be more useful in reducing the inflammation that develops during the later-phases of the allergic reactions as seen herein and other studies [19,33].

Conclusions
Unlike asthmatic reactions, for which several therapeutic agents are available, the continuous use of anti-anaphylactic drugs to manage food allergies is a therapeutic option that neither widely practiced nor promoted. The present study suggests that another component to the management of food allergies is to reduce the severity of systemic effects. In this regard the tripeptide feG was found to reduce the early and delayed systemic anaphylaxis provoked by oral antigen and this peptide could conceivably be taken after exposure to oral antigen and thereby limit the severity of delayed systemic reactions.

Materials and Methods
Animals and surgical procedures
All experiments described in this study were approved by The University of Calgary, Animal Care Committee in accordance with the guidelines of the Canadian Council on Animal Care. Male Hooded-Lister rats, weighing 150–170 g, were raised at the Life and Environmental Sciences Animal Resource Centre, The University of Calgary. The rats were housed under controlled lighting conditions (lights on from 7:00 H to 19:00 H), and provided with food and water ad libitum. All surgical procedures were performed with the animal under halothane anesthesia.

Sensitization to antigen and determination of antibody titer
The rats were sensitized by intraperitoneal injection of 10 µg of the antigen chicken ovalbumin (OA) (Grade V, Sigma Chemical Co., St. Louis, MO) and 10 mg of aluminum hydroxide (Al(OH)3) adjuvant in saline. This sensitization protocol results in an IgE-dependent anaphylaxis [47], and blood anti-OA IgE antibody titer was measured by passive cutaneous anaphylaxis 10 days after sensitization [3] using a small aliquot of blood (500 µl) obtained by cardiac puncture. The serum was then diluted serially (1:8 to 1:64) and 300 µl of each sample was injected into the shaved back of Sprague-Dawley rats. After 48 h, the rats were challenged with an intracardiac injection of a solution containing 2.5 mg of Evan’s blue and 5 mg of OA in a total volume of 2.5 mL. Evan’s blue extravasation was determined at the injection site, and a serum anti-OA antibody titer of 1:64 was required for an animal to be included in the experiments.

Antigen challenge and drug treatments
Four different groups of sensitized rats received one of the following treatments: (1) control animals received 0.9% saline only; (2) OA-challenged rats received 100 mg/kg of OA in 0.9% saline; (3) feG (Core Laboratories, Queen’s University, Kingston, ON) treated rats received 100 µg/kg of the peptide and antigen; and (4) dexamethasone treated rats received 4 mg/kg of Azium (Schering, Point Claire, QC) intraperitoneally.

Circulating leukocyte and bone marrow cell counts
Under halothane anesthesia whole blood (200 µl) was drawn by cardiac puncture at 0.5, 3 and 24 h after antigen challenge. Total leukocyte counts were determined using a Unopette microcollection system (Becton Dickinson, Franklin Lakes, NJ) and Hylite hemocytometer (Hauser Scientific, Boulder, CO). Another sample was used to prepare blood smears for microscopic leukocyte differentiation using a Giemsa stain. The hematocrit was determined with a microcapillary centrifuge.

The animals were killed with an overdose of sodium pentobarbital (MTC Pharmaceuticals, Cambridge, ON). The right femur bone marrow was eluted with 10 mL of phosphate buffered saline (PBS) and leukocyte counts were determined using a hemocytometer. The PBS had the following composition (mM): NaCl (137), KCl (2.7), Na2HPO4 (8.1), K2HPO4 (1.47), CaCl2 (1.19), MgCl2 (0.54), glucose (7.5), pH (7.4).

Measurement of plasma extravasation
The rats were anesthetized with halothane and injected with Evans Blue (20 mg/kg; Sigma) in 0.9% saline via cardiac puncture, and 10 min later they were orally challenged with OA and the drugs feG and dexamethasone were administered. Two other groups of rats were treated with feG or dexamethasone 12 hours before the OA challenge. Thirty minutes later, and under halothane anesthesia, the rats were perfused with 1 L/kg of PBS through the left ventricle. Pieces of heart, trachea, pinna, jejunum, and ileum tissue were excised, weighed, and placed in 1 mL of formamide (Sigma) for 72 h at 20°C. The optical density of the formamide was then read at 620 nm with a Beck-
man DU-50 spectrophotometer (Beckman Coulter Canada Inc., Mississauga, ON) and the amount of Evan’s Blue present was calculated from a standard curve.

**Myeloperoxidase measurements**

As a specific enzymatic marker of neutrophil infiltration into the tissue, myeloperoxidase (MPO) activity was determined in myocardial tissue and in lungs according previously described procedures [48]. Tissues (100–200 mg), excised from anesthetized rats were homogenized (Polytron homogenizer; Daigger, Vemon Hills, IL) in 0.5% hexadecyltrimethyl ammonium bromide (Sigma) dissolved in 50 mM potassium phosphate buffer at pH 6.0 for 1 min. Homogenates were then centrifuged at 4°C for 15 min at 1000 g. The supernatant was collected and reacted with 0.167 mg/mL o-dianisidine dihydrochloride (Sigma) and 0.005% H₂O₂ in 50 mM phosphate buffer at pH 6.0. The change in absorbance was measured spectrophotometrically at 460 nm. One unit of MPO activity is defined as the quantity of enzyme degrading 1 µmol of peroxide/min at 25°C.

**Intestinal histochemistry**

Eighteen hours after allergen-challenged or saline treatment mid-jejunal tissues were removed and whole mounted with pins and fixed in paraformaldehyde for 20 min at ~150% of resting tissue length and ~250% of resting tissue diameter. After fixing, the tissues were stripped of their mucosa, and histochemistry was performed on the muscularis [38]. The intestinal tissues were incubated for 24 h at 4°C with either ED9 or CD18 primary antibody (Cedarlane, Hornby, ON) at a 1:100 dilution) followed by three 5-min washes in PBS. The tissues were then incubated with a labeled secondary antibody (goat anti-mouse coupled to biotin) at 4°C overnight. After washing 3 times for 5 min with PBS buffer, avidin coupled horseradish peroxidase was added for 30 min at room temperature. Following further washes dianisobenzadine (DAB – Peroxidase Substrate Kit; Vector Laboratories, Burlingame, CA) was added until desired staining was attained. The intestinal tissues were then dry mounted on chrom alum-coated slides, cover slipped and viewed at >200 magnification. Counting was performed blind and the number of labeled cells determined in four random fields of each specimen.

**Leukocyte preparation and use**

Blood was collected by cardiac puncture into a 10 mL syringe from rats anesthetized with halothane. The blood was diluted with approximately 30 mL of PMN buffer (PBS buffer without calcium) in a 50 mL polypolypropylene centrifuge tube, and spun at 300 g for 15 min at 20°C. After the supernatant was discarded and the pellet washed with PMN buffer and spun again 200 g for 10 min at 20°C, the supernatant was discarded and the cells resuspended in 1 mL of PMN buffer, and total cell number determined using Trypan Blue exclusion on a hemocytometer. Cell differentials were determined on cell smears stained with May-Grünwald-Giemsa stain. Lymphocytes were 68.7% of the circulating white blood cells, neutrophils accounted for 20.4% and monocytes were 11.0%.

To isolate peritoneal leukocytes 10 mL of 0.9% sterile saline was injected intraperitoneally into halothane anesthetized rats and the abdomen massaged gently. After a clean laparotomy the peritoneal fluid (7 to 10 mL) was recovered and placed into a 50 mL polypolypropylene tube and diluted to 30 mL with PMN buffer. The cells were then prepared as described for blood leukocytes. Of the peritoneal cells 21.5% were neutrophils and 46.5% were macrophages.

**Statistical analysis**

Results were expressed as mean ± SEM and n is the number of animals. Statistical significance of differences between means was determined at p < 0.05, using, where appropriate, one-way analysis of variance (ANOVA) with the Student t-test applied for comparison of differences between two means.

---

**Table 2: Activation markers on interstitial cells. Effects of feG on staining of interstitial leukocytes in the jejunal muscle for CD18 and ED9 antigens.**

|                | CD18  | ED9-Macro | ED9-Neut |
|----------------|-------|-----------|----------|
| Saline – control | 7.4 ± 1.7a | 9.4 ± 2.6 | 13.1 ± 3.1 |
| Antigen         | 3.3 ± 0.5* | 13.5 ± 1.7 | 3.9 ± 0.7* |
| Antigen & feG   | 5.6 ± 1.2  | 11.6 ± 0.6 | 9.1 ± 1.1*# |

a = Values presented as mean ± SEM. N values = 4. Significance: P < 0.05; * less than saline; # greater than antigen
Abbreviations
CD11b, αM integrin; CD49d, α4 integrin; fEG, D-phenylalanine-D-glutamate-Glycine; MPO, myeloperoxidase; PBS, phosphate buffered saline; SGP-T, submandibular gland peptide-T

Authors’ contributions
Turesin F participated in the design of the study, managed the animals and carried out the cell counts and myeloperoxidase measurements. Sadri A performed the vascular permeability experiments. Davison JS participated in study design. Ronald Mathison conceived the study, participated in its coordination and drafted the manuscript. All authors read and approved the manuscript.

Acknowledgements
The technical assistance of Lorraine Oland and Cheryl Sank is greatly appreciated. The Heart and Stroke Foundation of Alberta and Salpep Biotechnology Inc supported this study.

References
1. Snider DP, Marshall JS, Perdue MH, Liang H: Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J Immunol 1991, 153:647-657.
2. Fargeas MJ, Theodourou V, Fioramonti J, Bueno L: Characterization of a potential anti-inflammatory effect of the PAF antagonists, CV-3988 and L-652,731 on the perturbation of intestinal motility provoked by anaphylaxis. Pediatr Allergy Immunol 1999, 10:162-169.
3. Scott RB, Diamant SC, Gall DG: Motility effects of intestinal anaphylaxis in the rat. Am J Physiol 1988, 255:G505-G511.
4. Scott RB, Tan DT: Mediation of altered motility in food protein induced intestinal anaphylaxis in Hooded-Lister rat. Can J Physiol Pharmacol 1996, 74:320-330.
5. Crowe SE, Suda K, Stanisz AM, Perdue MH: Intestinal permeability in allergic rats: nerve involvement in antigen-induced changes. Am J Physiol 1993, 264:G617-23.
6. Mourad FH, O’Dell J, Ogura E, Dias JA, Farthing MJ: Role of 5-hydroxytryptamine in intestinal water and electrolyte movement during gut anaphylaxis. Gut 1995, 36:533-537.
7. Sakamoto Y, Ohkita T, Yoshida H, Ohto K, Onobori M, Matsumoto T, Iikura Y, T Morohoshi: Time course of changes in the intestinal permeability of food-sensitized rats after oral allergen challenge. Pediatr Allergy Immunol 1998, 9:20-24.
8. Miamamba M, Tan DT, Oliver MR, Sharkey KA, Scott RB: Intestinal anaphylaxis induces Fos immunoreactivity in myenteric plexus of rat small intestine. Am J Physiol 1997, 272:G181-G189.
9. Jiang W, Kreis ME, Eastwood C, Kirkup AJ, Humphrey PP, Grundy D: S-HT(3) and histamine H(1) receptors mediate afferent nerve sensitivity to intestinal anaphylaxis in rats. Gastroenterol ogy 2000, 119:1267-1275.
10. Kreis ME, Muller M, Zittel TT, Glazier J, Grundy D: Mediators of neuronal activation in the rat brainstem following intestinal anaphylaxis. Neurosci Lett 2000, 289:45-48.
11. Scott RB, Tan DT, Sharkey KA: Effect of splanchnectomy on jejunal motility and fos expression in brain stem after intestinal anaphylaxis in rats. Am J Physiol Gastrointest Liver Physiol 2000, 279:G990-G997.
12. Levine S, Saltzman A: Distribution of small intestinal lesions in anaphylaxis of rats. Int Arch Allergy Immunol 1998, 115:312-315.
13. Mathison R, Davison JS, Befus AD: Microrccuclary changes associated with anaphylaxis in the Nippostrongylus brasiliensis sensitized rat. Am J Physiol 1990, 258:H126-H131.
14. Knippeifs LM, Houwen GF, Spanhak S, Penninks AH: An oral sensitization model in Brown Norway rats to screen for potential allergenicity of food proteins. Methods 1999, 19:78-82.
15. Jarisch R, Beringer K, Hemmer W: Role of food allergy and food intolerance in recurrent urticaria.Curr Probl Dermatol 1999, 28:64-73.
16. Pumphrey RS: Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000, 30:1144-50.
17. Rance F, Kanny G, Dung G, Monier-Vautrin DA: Food hypersensitivity in children: clinical aspects and distribution of allergens. Pediatr Allergy Immunol 1999, 10:33-38.
18. Lin Y, Schwartz LB, Curry A, Pelsa GR, Knight RJ, Lee HS, Baka-luchik J, Tenenbaum C, Westfal RE: Histamine and tryptase levels in patients with acute allergic reactions: An emergency department-based study. J Allergy Clin Immunol 2000, 106:65-71.
19. Mathison RD, Lo P, Davison JS, Scott B, Moore G: Attenuation of intestinal and cardiovascular anaphylaxis by the salivary gland tripeptide FEG and its D-isomeric analogue fEG. Peptide 1998, 19:1037-1042.
20. Mathison RD, Davison JS, Befus AD: The tripeptide fEG reduces perturbation of intestinal motility provoked by anaphylaxis. Proc West Pharmacol Soc 2001, 44:157-158.
21. Mathison RD, Daiman T, Oliver M, Befus AD, Davison JS, Scott B: Submandibular gland peptide-T (SGP-T) inhibits intestinal anaphylaxis. Dig Dis Sci 1997, 42:2378-2383.
22. Mathison RD, Befus AD, Davison JS: A novel submandibular gland peptide protects against endotoxin induced hypotension. Amer J Physiol 1997, 273:H1017-H1023.
23. Bloch KJ, Walker WA: Effect of the food allergen-induced intestinal anaphylaxis on the uptake of a bystander antigen. J Allergy Clin Immunol 1981, 67:312-316.
24. Jancar S, Siros MG, Carrier J, Braquet P, Siros P P: PAF induces rat plasma extravasation and releases eicosanoids during anaphylaxis. Inflammation 1991, 15:347-354.
25. Holme G, Pielcha P: The derivation of an inbred line of rats, which develop asthma-like symptoms following challenge with aerosolized antigen. Immunology 1981, 42:19-24.
26. Touaty E, Gerber F, Fournier M, Pariette R: SO2-induced bronchopulmonary decreases airway sensitivity with intratracheal ovalbumin in the rat. Bull Eur Physiopathol Respir 1986, 22:329-333.
27. Djuric V, Wang L, Bienenstock J, Perdue MH: Naloxone exacerbates intestinal and systemic anaphylaxis in the rat. Brain Be tides 1988, 9:207-101.
28. Filip JE, Telemarie S, Battistini B, Siros P, D’Orleans-Juste P: Increased plasma levels of endothelin during anaphylactic shock in the guinea-pig. Eur J Pharmacol 1993, 239:211-236.
29. Revenas B, Smedegard G, Saldeen T, Fredholm BB, Strandberg K: Anaphylactic shock in monkeys passively sensitized with human reaginic serum. II. Respiratory mechanics, hematology and metabolism. Acta Physiol Scand 1981, 111:249-257.
30. Altenburg SP, Martins MA, Silva PM, Bozza PT, Tibirica EV, Cordeiro RS, Carvalho-Neto HC: Systemic neutrophilia observed during anaphylactic shock in rats is inhibited with intratracheal ovalbumin in the rat. Am J Physiol 1993, 264:G617-G623.
31. Mathison R, Lo P, Tan D, Scott B, Davison JS: The tripeptide fEG reduces endotoxin-provoked perturbation of intestinal motility and inflammation. Neugastroenterol Motil 2001, 13:599-603.
32. Mathison R, Lo P, Tan D, Scott B, Davison JS: Effect of orally induced anaphylactic shock in dogs. J Physiol 1991, 260:H744-H751.
33. Mathison R, Woodman R, Davison JS: Regulation of leukocyte adhesion to heart by the tripeptides fEG and fEG(NHz). Can J Physiol Pharmacol 2001, 79:785-792.
39. Reinhart PH, Ward CA, Giles WR, Kubes P: Emigrated rat neutrophils adhere to cardiac myocytes via \( \alpha_4 \)-integrin. Circ Res 1997, 81:196-201

40. Leuenroth S, Isaacson E, Lee C, Keeping H, Simms HH: Integrin regulation of polymorphonuclear leukocyte apoptosis during hypoxia is primarily dependent on very late activation antigens 3 and 5. Surgery 1997, 122:153-62

41. Betsuyaku T, Liu F, Senior RM, Haug JS, Brown EL, Jones SL, Matsushita K, Link DC: A functional granulocyte colony-stimulating factor receptor is required for normal chemoattractant-induced neutrophil activation. J Clin Invest 1999, 103:825-32

42. Horwitz LD, Kaufman D, Kong Y: An antibody to leukocyte integrins attenuates coronary vascular injury due to ischemia and reperfusion in dogs. Am J Physiol 1997, 272:H618-24

43. Adcock IM: Glucocorticoid-regulated transcription factors. Pulm Pharmacol Ther 2001, 14:211-9

44. Filep JG, Delalandre A, Payette Y, Foldes-Filep E: Glucocorticoid receptor regulates expression of L-selectin and CD11/CD18 on human neutrophils. Circulation 1997, 96:295-301

45. Marone G, de Crescenzo G, Adt M, Patella V, Arbustini E, Genovese A: Immunological characterization and functional importance of human heart mast cells. Immunopharmacology 1995, 31:1-18

46. Biasucci LM, Colizzi C, Rizzello G, Vitrella G, Crea F, Liuzzo G: Role of inflammation in the pathogenesis of unstable coronary artery diseases. Scand J Clin Lab Invest Suppl 1999, 230:12-22

47. Perdue MH, Chung M, Gall DG: Effect of intestinal anaphylaxis on gut function in the rat. Gastroenterology 1984, 86:391-397

48. Grisham MB, Hernandez LA, Granger DN: Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am J Physiol 1986, 251:G567-G574